Weining Wang1, Weng Khong Lim2, Hui Sun Leong3, Fui Teen Chong3, Tony K H Lim4, Daniel S W Tan5, Bin Tean Teh3, N Gopalakrishna Iyer6. 1. Department of Surgical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore. 2. Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore. 3. Cancer Therapeutics Research Laboratory, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore. 4. Department of Pathology, Singapore General Hospital, Outram Road, Singapore 169610, Singapore. 5. Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore; Department of Medical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore. 6. Department of Surgical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore; Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore; Cancer Therapeutics Research Laboratory, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore. Electronic address: gopaliyer@yahoo.com.
Abstract
OBJECTIVES: Extracapsular spread (ECS) is an important prognostic factor for oral squamous cell carcinoma (OSCC) and is used to guide management. In this study, we aimed to identify an expression profile signature for ECS in node-positive OSCC using data derived from two different sources: a cohort of OSCC patients from our institution (National Cancer Centre Singapore) and The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma (HNSCC) cohort. We also sought to determine if this signature could serve as a prognostic factor in node negative cancers. MATERIALS AND METHODS: Patients with a histological diagnosis of OSCC were identified from an institutional database and fresh tumor samples were retrieved. RNA was extracted and gene expression profiling was performed using the Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray platform. RNA sequence data and corresponding clinical data for the TCGA HNSCC cohort were downloaded from the TCGA Data Portal. All data analyses were conducted using R package and SPSS. RESULTS: We identified an 11 gene signature (GGH, MTFR1, CDKN3, PSRC1, SMIM3, CA9, IRX4, CPA3, ZSCAN16, CBX7 and ZFP3) which was robust in segregating tumors by ECS status. In node negative patients, patients harboring this ECS signature had a significantly worse overall survival (p=0.04). CONCLUSIONS: An eleven gene signature for ECS was derived. Our results also suggest that this signature is prognostic in a separate subset of patients with no nodal metastasis Further validation of this signature on other datasets and immunohistochemical studies are required to establish utility of this signature in stratifying early stage OSCC patients.
OBJECTIVES: Extracapsular spread (ECS) is an important prognostic factor for oral squamous cell carcinoma (OSCC) and is used to guide management. In this study, we aimed to identify an expression profile signature for ECS in node-positive OSCC using data derived from two different sources: a cohort of OSCC patients from our institution (National Cancer Centre Singapore) and The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma (HNSCC) cohort. We also sought to determine if this signature could serve as a prognostic factor in node negative cancers. MATERIALS AND METHODS:Patients with a histological diagnosis of OSCC were identified from an institutional database and fresh tumor samples were retrieved. RNA was extracted and gene expression profiling was performed using the Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray platform. RNA sequence data and corresponding clinical data for the TCGA HNSCC cohort were downloaded from the TCGA Data Portal. All data analyses were conducted using R package and SPSS. RESULTS: We identified an 11 gene signature (GGH, MTFR1, CDKN3, PSRC1, SMIM3, CA9, IRX4, CPA3, ZSCAN16, CBX7 and ZFP3) which was robust in segregating tumors by ECS status. In node negative patients, patients harboring this ECS signature had a significantly worse overall survival (p=0.04). CONCLUSIONS: An eleven gene signature for ECS was derived. Our results also suggest that this signature is prognostic in a separate subset of patients with no nodal metastasis Further validation of this signature on other datasets and immunohistochemical studies are required to establish utility of this signature in stratifying early stage OSCC patients.
Authors: Yasmin Ghantous; Mohamed Omar; Esther Channah Broner; Nishant Agrawal; Alexander T Pearson; Ari J Rosenberg; Vasudha Mishra; Alka Singh; Imad Abu El-Naaj; Peter A Savage; David Sidransky; Luigi Marchionni; Evgeny Izumchenko Journal: Int J Cancer Date: 2021-10-14 Impact factor: 7.396
Authors: Kah Yee Goh; Kah Weng Lau; Terence You De Cheng; Su Chin Tham; Chwee Teck Lim; Narayanan Gopalakrishna Iyer; Su Bin Lim; Darren Wan-Teck Lim Journal: Cancer Commun (Lond) Date: 2022-03-02
Authors: Andre Luiz Vettore; Kalpana Ramnarayanan; Gregory Poore; Kevin Lim; Choon Kiat Ong; Kie Kyon Huang; Hui Sun Leong; Fui Teen Chong; Tony Kiat-Hon Lim; Weng Khong Lim; Ioana Cutcutache; John R Mcpherson; Yuka Suzuki; Shenli Zhang; Thakshayeni Skanthakumar; Weining Wang; Daniel S W Tan; Byoung Chul Cho; Bin Tean Teh; Steve Rozen; Patrick Tan; N Gopalakrishna Iyer Journal: Genome Med Date: 2015-09-23 Impact factor: 11.117